
    
      Up to 160 patients with ARDS will be randomized to receive either IC14 at a dosage of 4 mg/kg
      on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 or placebo for 4 days beginning
      within 48 hours of meeting inclusion criteria. Study participation will be for 28 days.
    
  